<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">Cardiovascular disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>) is the leading cause of <z:hpo ids='HP_0011420'>death</z:hpo> among people with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Recent attention has focused on <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> as an additional risk factor in people with <z:mp ids='MP_0002055'>diabetes</z:mp> since their excess <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> risk is not entirely explained by traditional <z:e sem="disease" ids="C0850624" disease_type="Disease or Syndrome" abbrv="">cardiovascular risk factors</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Clinical trials of intensive <z:chebi fb="105" ids="17234">glucose</z:chebi> control to reduce <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> events have been equivocal, but recent epidemiological studies have shown that HbAlc, a measure of <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e>, predicts incident cardiovascular events </plain></SENT>
<SENT sid="3" pm="."><plain>This review, which focuses on type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, summarizes (i) the epidemiological literature examining the relation between glycaemic status, as assessed by glycated <z:chebi fb="34" ids="35143">haemoglobin</z:chebi> (HbAlc) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>, (ii) the controversy regarding treatment goals for HbAlc in terms of preventing microvascular disease vs. macrovascular disease and (iii) on-going clinical trials of intensive glycaemic control for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> prevention </plain></SENT>
</text></document>